Scrofula associated with a patient receiving adalimumab therapy for Crohn disease

Clin Exp Dermatol. 2021 Jan;46(1):216-218. doi: 10.1111/ced.14434. Epub 2020 Sep 15.

Authors

W T N Hunt¹, J F Wheeler¹, N A Kennedy², T Burden³, E J McGrath¹

Affiliations

¹ Departments of, Department of, Dermatology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
² Department of, Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
³ Department of, Respiratory Medicine, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.

PMID: 32931629
DOI: 10.1111/ced.14434

No abstract available

Publication types

Case Reports

MeSH terms

Adalimumab / adverse effects*
Adalimumab / therapeutic use
Anti-Inflammatory Agents / adverse effects
Anti-Inflammatory Agents / therapeutic use
Antitubercular Agents / administration & dosage
Antitubercular Agents / therapeutic use
Crohn Disease / complications
Crohn Disease / drug therapy*
Humans
Immunocompromised Host / immunology
Latent Infection / chemically induced*
Latent Tuberculosis / diagnosis*
Latent Tuberculosis / drug therapy
Latent Tuberculosis / etiology
Male
Middle Aged
Tuberculosis, Lymph Node / diagnosis*
Tuberculosis, Lymph Node / drug therapy
Tuberculosis, Lymph Node / etiology

Substances

Anti-Inflammatory Agents
Antitubercular Agents
Adalimumab